ACTG--267 PHARMACOKINETICS OF THALIDOMIDE IN SUBJECTS WITH HIV-1 INFECTION

ACTG--267 沙利度胺在 HIV-1 感染受试者中的药代动力学

• 批准号: 6297348
• 负责人: Charles Michael van der Horst
• 金额: $ 0.02万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6297348
• 关键词: AIDS therapy; HIV infections; antiviral agents; clinical research; dosage; drug screening /evaluation; drug tolerance; human immunodeficiency virus 1; human subject; human therapy evaluation; immunology; microorganism disease chemotherapy; pharmacokinetics; thalidomide

ACTG 267: This study will procure data on the tolerability, safety, antiviral activity and immunologic effects of thalidomide in HIV infected subjects. In addition, information on the pharmacokinetics and antiviral and immunologic activity of the drug at three different doses regimes will be obtained.

ACTG 267：本研究将获取有关沙利度胺对 HIV 感染者的耐受性、安全性、抗病毒活性和免疫作用的数据。 此外，还将获得药物在三种不同剂量方案下的药代动力学以及抗病毒和免疫活性的信息。